Pharma Could Be Going Back To Negotiating Table On Federal Drug Cost Cuts
Executive Summary
After its protracted deal-making on the health care reform bill in 2009 and 2010, the biopharmaceutical industry may be headed back to negotiations with the White House on proposals to cut drug spending in Medicare.
You may also be interested in...
Can Jersey City Be A Cure For What Ails Pharma?
One of the highlights of the Pharmaceutical Research & Manufacturers of America's annual meeting in Jersey City, N.J., was a fill-in-the-blank exercise.
Can Jersey City Be A Cure For What Ails Pharma?
One of the highlights of the Pharmaceutical Research & Manufacturers of America's annual meeting in Jersey City, N.J., was a fill-in-the-blank exercise.
FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.